Compare FRST & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | PGEN |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 1.5B |
| IPO Year | 2006 | N/A |
| Metric | FRST | PGEN |
|---|---|---|
| Price | $13.38 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 92.0K | ★ 4.7M |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $138,816,000.00 | $6,309,000.00 |
| Revenue This Year | $13.75 | $342.78 |
| Revenue Next Year | $35.05 | $478.46 |
| P/E Ratio | $39.52 | ★ N/A |
| Revenue Growth | 33.08 | ★ 59.20 |
| 52 Week Low | $7.59 | $0.69 |
| 52 Week High | $13.88 | $5.23 |
| Indicator | FRST | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 74.72 | 63.06 |
| Support Level | $13.23 | $3.64 |
| Resistance Level | $13.88 | $3.75 |
| Average True Range (ATR) | 0.38 | 0.27 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 81.49 | 85.71 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.